

Published on *UCSF Department of Radiation Oncology* (<http://radonc.ucsf.edu>)

[Home](#) > [Our Team](#) > [Medical Faculty](#) > [David Raleigh](#)

---

## David Raleigh

---

### David R. Raleigh, M.D., Ph.D

**Assistant Professor**  
**Department of Radiation Oncology**



University of California, San Francisco  
505 Parnassus Avenue, Room L-08  
San Francisco, CA 94143  
Clinic Phone: 415 353-8950  
Fax: 415 353-8679

**Research Website** <sup>[1]</sup>

[Make A Gift](#)  
[Support Our Research](#)

<sup>[2]</sup>

### Professional Focus

Dr. Raleigh is specialized in the treatment and investigation of central nervous system tumors in adult and pediatric patients. His research focuses on the biologic processes that cause

brain tumors to grow. His primary goal is to understand how developmental signaling pathways cause cancer to shed light on the fundamental mechanisms of developmental biology and identify novel treatments for cancer patients. His laboratory research makes use of biochemistry, molecular biology, cell biology, mouse genetics, genomics, bioinformatics and pharmacology to gain new insights into the molecular determinants of human malignancies.

## Education

2000-2004	University of California, Berkeley	BA (Honors)	Molecular and Cell Biology
2000-2004	University of California, Berkeley	BA (Honors)	Cognitive Science
2005-2012	University of Chicago	Medical Doctorate	Pritzker School of Medicine
2007-2010	University of Chicago	Doctorate of Philosophy	Pathology
2005-2012	University of Chicago	MD/PhD Student	NIH MSTP
2012-2013	Kaiser Permanente Santa Clara	Intern Physician	Internal Medicine
2013-2017	University of California, San Francisco	Resident Physician	Radiation Oncology
2015-2016	University of California, San Francisco	Chief Resident Physician	Radiation Oncology

## Professional Experience

2017-present	University of California, San Francisco	Assistant Professor	Radiation Oncology
2017-present	University of California, San Francisco	Principal Investigator	Brain Tumor Center
2017-present	Children's Oncology Group	Principal Investigator	ANBL 1232

## Awards & Honors

2001-2004	Dean's Honor Roll, UC Berkeley College of Letters and Science		
2004	Graduation with High Honors, UC Berkeley Department of Molecular Cell Biology		
2004	Graduation with High Honors, UC Berkeley Department of Cognitive Science		
2004	Phi Beta Kappa Inductee, UC Berkeley		

2009	Travel Award, FASEB Gastrointestinal Tract XIII Annual Meeting
2009	Poster of Distinction, Digestive Disease Week Annual Meeting
2009	Outstanding Oral Presentation, U Chicago Annual Biomedical Sciences Cluster Retreat
2010	Takeda Travel Award, Experimental Biology Annual Meeting
2011	Top Quartile in Graduating Class, U Chicago Pritzker School of Medicine
2011	Career Development Award, U Chicago Medical Scientist Training Program
2012	Outstanding Performance, U Chicago Department of Radiation and Cellular Oncology
2013	Teaching Award, Kaiser Permanente Santa Clara
2013-2017	ABR Holman Research Pathway, UCSF Department of Radiation Oncology
2015	Resident Research Travel Award, UCSF Clinical & Translational Science Institute
2016	Semi-Finalist, Burroughs Wellcome Fund Medical Scientist Career Award
2016	Roentgen Research Award, Radiological Society of North America
2016	Biology Abstract Travel Award, American Society for Radiation Oncology Annual Meeting
2016	Poster of Distinction, Association of Residents in Radiation Oncology
2016	Top Young Investigator Awardee, ASCO Scientific Career Development Retreat
2016	PSSP Scholar, UCSF Physician Scientist Scholar Program
2017	Young Oncologist Travel Grant, American Radium Society Annual Meeting
2017	Poster of Distinction, American Radium Society Annual Meeting

#### Recent Significant Publications :

Raleigh DR, Algazi A, Arron ST, Neuhaus IM, Yom SS. **Induction hedgehog pathway inhibition followed by combination modality radiotherapy for basal cell carcinoma.** Br J Dermatol. 2015. 173:544-546. PMID: 25702621.

Oskvarek JJ, Brower JV, Mohindra P, Raleigh DR, Chmura SJ, Golden DW. **Educational impact of a structured radiation oncology clerkship curriculum: an inter-institutional comparison.** J Am Coll Radiol. 2016. 16: 30632-30639. PMID: 27652570.

Magill ST, Lau D, Raleigh DR, Sneed PK, McDermott MW. **Surgical resection and interstitial 125I brachytherapy for high grade meningioma: a 25 year series.** Neurosurg. 2017. 80:409-416. PMID: 27258768.

Raleigh DR?, Solomon DA?, Lloyd SA, Lazar A, Garcia MA, Sneed PK, Clarke JL, McDermott

MW, Berger MS, Tihan T, Haas-Kogan DA. **Histopathologic review of pineal parenchymal tumors identifies novel morphologic subtypes and prognostic factors for outcome.** Neuro Oncol. 2017. 19:78-88. PMID: 27282397.

Garcia MA, Lazar A, Duriseti S, Raleigh DR, Hess C, Fogh SE, Barani IJ, Nakamura JL, Larson DA, Theodosopoulos P, McDermott MW, Sneed PK, Braunstein SE. **Discovery of additional brain metastases on the day of stereotactic radiosurgery: risk factors and outcomes.** J Neurosurg. 2017. 126:1756-1763. PMID: 27367235.

Raleigh DR, Seymour ZA, Tomlin B, Theodosopoulos PV, Berger MS, Aghi MK, Geneser SE, Krishnamurthy D, Fogh SE, Sneed PK, McDermott MW. **Resection and brain brachytherapy with permanent iodine-125 seeds for brain metastasis.** J Neurosurg. 2017. 126:1749-1755. PMID: 27367240.

Raleigh DR, Tomlin B, Del Buono B, Roddy E, Sear K, Byer L, Felton E, Banerjee A, Torkildson J, Samuel D, Horn B, Braunstein SE, Haas-Kogan DA, Mueller S. **Survival after chemotherapy and stem cell transplant followed by delayed craniospinal irradiation is comparable to upfront craniospinal irradiation in pediatric embryonal brain tumor patients.** J Neurooncol. 2017. 131:359-368. PMID: 27778212.

Kline CN, Joseph NM, Grenert JP, van Ziffle J, Talevich E, Onodera C, Aboian M, Cha S, Raleigh DR, Braunstein SE, Torkildson J, Samuel D, de Alba Campomanes A, Banerjee A, Butowski N, Raffel C, Tihan T, Bollen AW, Phillips JJ, Korn M, Yeh I, Bastian BC, Gupta N, Mueller S, Perry A, Nicolaidis T, Solomon DA. **Targeted next-generation sequencing of pediatric brain tumor patients improves diagnosis, identified pathogenic germline mutations, and directs targeted therapy.** Neuro Oncol. 2017. 19:699-709. PMID: 27978508.

Braunstein SE?, Raleigh DR?, Bindra R, Mueller S, Haas-Kogan DA. **Pediatric high grade gliomas.** J Neurooncol. In press.

Vasudevan HN?, Raleigh DR?, Johnson J, Garsa AA, Theodosopoulos PV, Aghi MK, Ames C, McDermott MW, Barani IJ, Braunstein SE. **Management of chordoma and chondrosarcoma with fractionated stereotactic radiotherapy.** Neurosurg Focus. In press.

\*/

UCSF Main Site

© 2015 The Regents of the University of California

---

**Source URL:** <http://radonc.ucsf.edu/david-raleigh>

**Links**

[1] <http://raleighlab.ucsf.edu>

[2] <http://radonc.ucsf.edu/make-gift>